Corbus Pharmaceuticals CRBP is not your typical cannabis stock involved in cultivation, processing, or sales of marijuana ...

"We are excited about the potential of BDC-3042 to help patients with cancer. This initial dose-escalation study demonstrated a favorable safety profile, dose-dependent biologic activity, and ...

Researchers reevaluated the use of opioid prescriptions in an acute palliative care unit among patients with advanced cancer.

"By confirming both safety and efficacy in the dose escalation part of Phase 1/2 study, CNT201 offers a new non-surgical treatment option for patients with Dupuytren's contracture. We aim to ...

WALTHAM, Mass., May 01, 2025--(BUSINESS WIRE)--Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a ...

This first-in-human dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of LCL161 in patients with advanced solid tumors. A second part of ...

RESULTS: Thirty-eight patients were enrolled. Median follow-up was 16 months. Twenty-four patients were not eligible for radiation dose escalation beyond 73.6 Gy because of persistently abnormal TGFβ ...

In the monotherapy arm, dose escalation continued to the maximum feasible dose. No dose-limiting toxicities and no treatment-emergent adverse events leading to treatment discontinuation were observed.

Statement from Woo Jong Lee, CEO of Connext "By confirming both safety and efficacy in the dose escalation part of Phase 1/2 study, CNT201 offers a new non-surgical treatment option for patients ...

As of the January 10, 2025 data cutoff, 52 patients with advanced solid tumors were enrolled to the dose escalation portion of the trial across dose levels ranging from 50 mg to 800 mg.

This Phase I dose-escalation study in patients with advanced solid tumors was performed to determine the MTD, overall safety, pharmacokinetic (PK) profile and anti-tumor activity of afatinib ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...